Abstract
N-methyl-D-aspartate receptor (NMDAR) encephalitis is a potentially treatable condition, although a small proportion of patients remains refractory to immunotherapy. Recently, bortezomib, a proteasome inhibitor used in multiple myeloma, has been used in NMDAR encephalitis and neuromyelitis optica. We performed a systematic review regarding the use of bortezomib in NMDAR encephalitis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
